Board of Directors

Michael Beecham is a Partner at Petrichor Healthcare Capital Management, where he aligns customized investment structures and support for interests in the life sciences industry. Prior to holding this position, he served as Board Observer at Fennec Pharmaceuticals, Leukocare AG, and Clearpoint Neuro helping to guide companies in capital management. Michael also spent time at Vatera Healthcare Partners and OrbiMed Advisors working in special structure financing.

Dr. Fred Cohen is a Co-Founder of Monograph Capital and Senior Managing Director at Vida Ventures. He has been at the forefront of life sciences focused endeavours for over four decades, holding positions including Chief of the Division of Endocrinology and Metabolism at University of California San Francisco (UCSF) and Managing Partner at TPG Biotechnology. Fred is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. He has been the recipient of awards and honors including the Burroughs-Welcome New Initiatives in Malaria Award, the LVMH Science Pour L’Art Prize, a Searle Scholars Award and Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation.

Karen Flynn retired from Catalent, Inc. (NYSE CTLT) in the position of President of Biomodalities. She previously worked in C-level commercial and General Management roles at Catalent and West Pharmaceutical Services, serving as Chief Commercial Officer and Division President at both companies. Karen is now leveraging more than 35 years of commercial industry savvy into board positions with Quanterix Corporation (NASDAQ:QTRX), Sotera Health (NASDAQ: SHC), Stevanato Group (NYSE: STVN), and GermFree, where her expertise helps the innovators of today prosper. Karen also serves on the Board of Trustees for the Franklin Institute.

Tim Funnell is a Partner at Monograph Capital and one of the founding investors of Ascend. Tim first served as CEO, and his legacy scaffolds the structure of Ascend today. For more than a decade, Tim’s focus has been in the cell and gene therapy industry working with various startups, including via Syncona as a company builder and with ground-breaking companies like Gyroscope (AAV) and Autolus (CAR-Ts). With experience in the USA and the UK, he has transformed the future of biomanufacturing through transparency, connection, and capital investment.

Justin Kern is Chairman of the Board at Elo Life Systems and a partner at DCVC Bio. With his formal training in microbiology and time spent researching in the fields of biochemistry and microbiology, Justin brings incomparable experience and resources to his advisory roles in the biotechnology sector. In addition to his interests across the life sciences industry, Justin serves as a director with Paine Schwartz Partners investing. He holds a PhD in microbiology from University of Chicago and was a NRSA postdoctoral scholar at Stanford University.

Dr. Evis Hursever is the CEO of EW Healthcare Partners, leading the firm’s investment practice and team. Evis has led the investments in Cognate Bioservices (acquired by Charles River Laboratories), EUSA Pharma II (acquired by Recordati S.p.A.), Biotoscana (acquired by Knight Therapeutics), Laboratoires Majorelle, Grundium Oy, Boiron and GermFree. She currently serves on the boards of Majorelle, Germfree. Grundium and Boiron. Prior to joining EW, Dr. Hursever spent more than a decade in life sciences and healthcare management, consulting, and investment, and remains committed to generating long-term sustainability for numerous healthcare companies, ranging across sectors, stages, and geographies

Andrew Kozlov is the Co-Founder, Managing Partner, and CFO of 4BIO Capital, a London-based venture capital firm. Since 2009, he has served as Founder, Partner, and CIO of biotech investment practice at Enso Ventures, in addition to spending time on the boards of several public and private biotechnology companies, including Redpin Therapeutics Inc, Egalet Corp (NASDAQ: EGLT), Image Analysis, and Vascular Flow Technologies. Prior to this, Andrew worked in finance and structure at McKinsey & Co, HSBC Bank Plc and Profine GmbH.

Bali Muralidhar is Managing Partner, Chief Investment Officer and COO at transatlantic life sciences investment firm, Abingworth. With more than 15 years of healthcare and life sciences expertise, he represents multiple companies in the portfolio. Prior to joining Abingworth, Bali worked in high profile investment firms participating in deal oversight and was named among Financial News’ Rising Stars in European Private Equity under 40 in 2018. In addition to publishing more than a dozen peer reviewed papers, Bali was a medical doctor at Addenbrooke’s Hospital in Cambridge and The John Radcliffe Hospital in Oxford, as well as a Bye-Fellow in Medical Sciences at Downing College, Cambridge teaching pathology, surgery, and medicine.

Andrew Sinclair is a Managing Director at Abingworth. He is actively involved on the boards of companies within the Abingworth portfolio, including Adicet Bio, Entact Bio, Soleno and Ascend. He was previously on the boards of Verona Pharma and Sierra Oncology and was also an observer on the boards of HilleVax and Phathom. With a background in investment research in the mid-cap pharmaceutical sector, Andrew has held biotechnology analyst positions at multiple investment banks and qualified as a chartered accountant with KPMG.

Jia-Yi is a Partner at Cathay Health based in London, where she focuses on tech bio investments across life science tools, diagnostics, medtech and digital health, including serving on the board at Ascend. Her multidisciplinary background spans two decades in investments, venture building, business management, and academic research. Jia-Yi is a published author in the fields of microbial genetics and biophysics in several peer-reviewed scientific journals and earned her MSc in Civil & Environmental Engineering from MIT, where she was a recipient of the Schoettler and Linden Earth System Fellowships.